Actigraphy Sensors and PSG Devices Market By Product Type (Actigraphy Sensors, Polysomnography Devices); By Application (Sleep Apnea, Insomnia & Circadian Rhythm Disorders, Narcolepsy & Others); By End User (Sleep Labs, Hospitals, Home Care, Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Actigraphy Sensors And Polysomnography ( PSG ) Devices Market will witness a robust CAGR of 8.7% , valued at $2.9 billion in 2024 , and is expected to appreciate and reach $5.1 billion by 2030 , confirms Strategic Market Research.

 

Actigraphy and PSG devices are at the core of sleep and circadian rhythm diagnostics, offering a window into disorders like insomnia, obstructive sleep apnea (OSA), narcolepsy, and circadian rhythm sleep-wake disorders (CRSWDs). These devices not only play a clinical diagnostic role but also act as critical tools in sleep research, occupational medicine, and digital therapeutics.

 

In 2024, this market holds strategic relevance due to the sharp rise in sleep-related health issues driven by lifestyle stress, aging populations, and increasing awareness about sleep health. Over 936 million people worldwide suffer from sleep apnea , a key target condition addressed by PSG devices. Meanwhile, wearable actigraphy sensors are finding adoption in longitudinal health tracking, clinical trials, and remote care models.

 

Several macro forces are shaping the trajectory of this market:

• Technology convergence: Cloud-based platforms, AI-powered data analysis, and wearable integration are redefining diagnostics.

• Global regulatory momentum: Reimbursement frameworks for sleep studies are expanding across the U.S., Europe, and parts of Asia.

• Rising digital health investments: Venture capital interest and hospital IT modernization efforts are fueling device adoption.

 

Strategically, this market connects multiple stakeholders:

• OEMs (Original Equipment Manufacturers) — from startups designing wearable actigraphy rings to multinationals developing high-precision PSG systems.

• Healthcare providers — including sleep labs, tertiary hospitals, and home-based care coordinators.

• Government and public health bodies — advocating for early diagnosis to reduce comorbidity burdens.

• Investors and digital health accelerators — fueling innovation in remote diagnostics and data monetization models.

The market’s inflection point lies in the convergence of regulated clinical-grade devices with consumer-centric usability. As healthcare delivery shifts toward decentralized, data-first models, actigraphy and PSG will underpin a new era of neuro- behavioral health management.

 

Market Segmentation And Forecast Scope

The actigraphy sensors and PSG devices market is segmented across four core dimensions to accurately capture its evolving scope and revenue dynamics from 2024 to 2030 :

By Product Type

• Actigraphy Sensors

• Polysomnography (PSG) Devices

Actigraphy Sensors are compact, wearable devices that measure motion-based activity and rest cycles, increasingly adopted in ambulatory sleep studies and wellness programs. They dominate in terms of volume but trail in revenue due to lower unit costs. In 2024 , they account for approximately 41% of the market.

Polysomnography Devices , on the other hand, remain the gold standard in sleep diagnostics. These devices monitor multiple physiological signals—EEG, EOG, EMG, airflow, oxygen saturation, and ECG—and are primarily used in sleep laboratories or hospitals. Their higher ASPs (Average Selling Prices) contribute to a larger revenue share.

Expert insight: “While PSG devices dominate revenue, the exponential rise in demand for longitudinal, non-invasive sleep tracking has put actigraphy on a fast-growth path, especially in remote care and population studies.”

 

By Application

• Sleep Apnea Diagnosis

• Insomnia & Circadian Rhythm Disorders

• Narcolepsy & Hypersomnia

• Others (ADHD, Mood Disorders, etc.)

Sleep Apnea Diagnosis continues to be the largest and most lucrative segment, fueled by increased screening mandates and high prevalence. However, Insomnia & Circadian Rhythm Disorders is emerging as the fastest-growing segment , particularly in North America and Asia, driven by digital therapeutic integrations and employer-funded wellness programs.

 

By End User

• Sleep Laboratories

• Hospitals & Clinics

• Home Care Settings

• Academic & Research Institutions

Sleep Laboratories remain dominant due to their critical role in comprehensive PSG testing. However, Home Care Settings are growing rapidly as miniaturized PSG systems and actigraphy sensors enable at-home sleep testing with real-time physician connectivity.

“The decentralization of diagnostics is reshaping end-user hierarchies. Portable PSG systems and wearable actigraphy are extending sleep care beyond the clinic,” notes a digital health strategist from Singapore General Hospital.

 

By Region

• North America

• Europe

• Asia Pacific

• LAMEA (Latin America, Middle East & Africa)

North America leads in market share due to advanced infrastructure, favorable reimbursement, and strong OEM presence. Meanwhile, Asia Pacific is anticipated to grow at the highest CAGR , with countries like China, India, and South Korea investing in sleep medicine capacity and digital health acceleration.

This segmentation framework allows stakeholders to evaluate performance across devices, indications, care settings, and global geographies—offering precision for strategic planning and investment decisions.

 

Market Trends And Innovation Landscape

The actigraphy sensors and PSG devices market is undergoing a dynamic evolution, driven by technological innovation, clinical validation, and shifting consumer behavior . Between 2024 and 2030, three dominant innovation currents are expected to define the competitive and functional trajectory of this market:

1. Wearable Intelligence and Sensor Miniaturization

Actigraphy devices are rapidly transforming from simple motion detectors into AI-enhanced biosignal platforms . New-generation sensors now capture heart rate variability, peripheral temperature, and even light exposure—enabling multi-dimensional circadian rhythm analysis.

Startups and med-tech OEMs are introducing ring-based or patch-style wearables that are less intrusive and more patient-friendly , especially for long-term, outpatient monitoring. These devices are increasingly used in:

• Sleep behavior studies across large cohorts

• Monitoring of insomnia treatment efficacy

• Behavioral health research

“The rise of sensor miniaturization is empowering sleep science to extend beyond the lab—into real life, at real scale,” notes a principal researcher from a European clinical neurophysiology consortium.

 

2. AI-Powered PSG Data Analysis

Traditional PSG generates vast datasets from up to 16 channels of biosignals , making manual scoring labor-intensive and time-consuming. Today’s innovation focus is on automated PSG scoring using machine learning to detect:

• Apnea /hypopnea events

• Sleep architecture patterns (REM, NREM, arousals)

• Cardiopulmonary irregularities

AI-integrated PSG software is increasingly used in high-throughput sleep centers , where it reduces clinician load and speeds diagnostic turnaround. These advancements are also enabling tele-PSG workflows , where raw data is transmitted from the home to centralized scoring hubs.

 

3. Ecosystem Integrations with mHealth and Digital Therapeutics

Actigraphy sensors are now interfacing with mobile health platforms , enabling continuous patient engagement. Integration with sleep coaching apps, cognitive behavioral therapy (CBT-I) modules, and circadian alignment tools is expanding the role of actigraphy into personalized sleep medicine .

Leading health insurers and employers are piloting such tools in wellness programs, using actigraphy-derived data to incentivize behavioral change. This trend is generating new monetization channels beyond clinical sales, including:

• Subscription-based sleep analytics

• API access for digital health partners

• Licensing for pharma-sponsored trials

 

Recent Innovation Highlights

• AI-based PSG scoring tools received CE clearance in the EU (2023)

• Multi-sensor actigraphy wearables launched with photoplethysmography (PPG) and EDA tracking

• Strategic tech-health partnerships announced for sleep data integration into EHRs and population health systems

Innovation is no longer confined to hardware. It’s the orchestration of data, UX, and AI that’s defining competitive advantage.

 

Competitive Intelligence And Benchmarking

The global actigraphy sensors and PSG devices market is shaped by a combination of established medical device giants, specialized sleep tech companies, and emerging digital health innovators. The competitive landscape is characterized by portfolio diversification , AI integration , and geographic expansion , with companies vying to offer end-to-end solutions from diagnostics to data analytics.

Here are seven key players defining this market’s strategic contour:

1. Natus Medical Incorporated

A dominant force in PSG systems, Natus has a strong global footprint in neurology and sleep diagnostics. The company focuses on clinically validated PSG platforms , offering superior biosignal fidelity and multi-channel recording. Their strategy involves expanding into AI-enabled scoring tools and telehealth-compatible systems .

 

2. Philips Healthcare

Leveraging its robust position in hospital-grade equipment, Philips offers comprehensive PSG solutions under its Sleep & Respiratory Care division. Their NightBalance and Alice platforms have found adoption in both institutional and home sleep testing. Philips is also investing heavily in cloud-based sleep data platforms , fostering interoperability and remote monitoring.

 

3. SOMNOmedics

A European innovator, SOMNOmedics specializes in miniaturized PSG and actigraphy solutions. Its devices are known for wireless recording , multi-signal capability , and mobile compatibility . The company targets research institutions and decentralized sleep labs , maintaining a competitive edge through modular designs and open-source data access .

 

4. Fitbit (a Google company)

Though primarily a consumer brand, Fitbit has expanded into clinical-grade actigraphy through research collaborations. Select models are now used in longitudinal studies , wellness monitoring, and digital sleep therapy trials. Its advantage lies in scale, affordability , and API-ready platforms for third-party integration.

 

5. Compumedics Limited

Based in Australia, Compumedics is a global leader in sleep diagnostics and neurophysiology. Its Grael PSG/EEG series caters to sleep labs and hospitals seeking high-resolution, high-channel-count systems . The firm is integrating machine learning algorithms for automated analysis and real-time data streaming.

 

6. ActiGraph

 

ActiGraph focuses exclusively on actigraphy for clinical research and drug trials. It partners with CROs and pharma firms to enable 24/7 activity and sleep monitoring , particularly in CNS and metabolic studies. Its competitive strength lies in validated algorithms and data granularity tailored for FDA submissions .

 

7. Cadwell Industries

A longstanding name in neurodiagnostics , Cadwell offers PSG systems integrated with EEG, EMG, and respiratory diagnostics , enabling broader clinical use. The firm has a strong presence in North America and Europe , with a focus on hardware reliability and customized clinical configurations .

 

Competitive Themes and Differentiators:

• AI and automation are emerging as core differentiators, particularly in PSG data processing.

• End-to-end ecosystems (device + cloud + analytics) are gaining market share over standalone hardware.

• Companies like Fitbit and ActiGraph are pioneering non-traditional market entries by aligning with wellness and research verticals.

“The competition is no longer just about signal fidelity—it’s about delivering actionable insights with minimal patient friction,” says a digital health strategist advising U.S. sleep clinics.

 

Regional Landscape And Adoption Outlook

The adoption of actigraphy sensors and PSG devices varies significantly by region, driven by differences in healthcare infrastructure, reimbursement mechanisms, digital maturity, and public health awareness. While North America leads in both technology deployment and revenue, the highest growth trajectory is seen in Asia Pacific , where public health initiatives and private investments are expanding sleep diagnostics capacity.

North America

• Market Leader in 2024, accounting for over 40% of the global revenue.

• The U.S. benefits from a robust network of accredited sleep centers , broad insurance coverage (e.g., Medicare reimbursement for HST and PSG), and proactive employer-led wellness programs.

• Canada is also showing strong adoption, especially in remote PSG testing for rural areas.

• The presence of key players like Philips , Cadwell , and Natus further cements the region’s leadership.

“North America’s maturity lies in its dual-channel adoption—both hospital-grade PSG and consumer-integrated actigraphy,” observes a sleep medicine consultant at Johns Hopkins University.

 

Europe

• A highly regulated but innovation-friendly market.

• Germany, the UK, and the Netherlands are leading in the use of wearable actigraphy for both clinical trials and home-based therapy.

• Public reimbursement varies by country; Nordic nations are early adopters of digital therapeutics that integrate actigraphy data.

• EU-wide sleep research funding under Horizon Europe supports R&D in circadian health, creating white spaces for academic-industry collaboration.

 

Asia Pacific

• The fastest-growing region , projected to grow at a CAGR exceeding 11.5% through 2030.

• China and India are expanding sleep diagnostics infrastructure in Tier 1 and Tier 2 cities, often via private multispecialty hospital chains.

• Japan and South Korea are advanced markets for wearable actigraphy , largely due to high consumer tech adoption and employer-sponsored wellness programs.

• Governments are promoting early screening for sleep apnea due to its link with cardiovascular and metabolic disorders.

“Asia Pacific is leapfrogging traditional diagnostic models by adopting mobile PSG and AI-assisted actigraphy in decentralized setups,” reports a MedTech investor focused on emerging markets.

 

LAMEA (Latin America, Middle East & Africa)

• Represents an underserved but opportunistic region.

• Brazil leads Latin America in PSG adoption, supported by rising sleep apnea awareness and private insurance.

• In the Middle East, the UAE and Saudi Arabia are investing in digital health platforms, creating room for cloud-based PSG integration .

• Africa remains at the nascent stage , with sporadic uptake limited to urban centers and elite hospitals.

 

Comparative Snapshot: Regional Readiness and Barriers

Region	Readiness Level	Key Enablers	Major Barriers
North America	Very High	Reimbursement, OEM presence, awareness	High system cost in rural areas
Europe	High	Regulatory clarity, research networks	Country-specific insurance gaps
Asia Pacific	Moderate–High	Mobile health, rising disease burden	Clinical training and device validation lags
LAMEA	Low–Moderate	Urban investments, wellness trends	Infrastructure gaps, low awareness

While the market matures globally, the next frontier lies in enabling equitable access to sleep diagnostics—digitally, affordably, and at scale.

 

End-User Dynamics And Use Case

The adoption of actigraphy sensors and PSG devices is being shaped by an increasingly diverse end-user ecosystem. From large tertiary hospitals to home-based sleep diagnostics providers and academic researchers, stakeholders are integrating these technologies based on need, scale, and digital compatibility. Each end user brings a unique demand profile and value perspective.

1. Sleep Laboratories

• Sleep labs remain the primary setting for full-spectrum PSG testing , particularly for patients with complex comorbidities such as COPD, epilepsy, or neuromuscular disorders.

• These centers invest in high-channel PSG systems with advanced signal fidelity and EEG integration.

• Automated scoring and real-time remote physician access are driving operational efficiency.

 

2. Hospitals & Clinics

• General hospitals and outpatient specialty clinics use PSG systems to diagnose sleep apnea , hypersomnia, and parasomnias.

• Many facilities are adopting portable PSG kits to extend services beyond the lab and improve patient convenience.

• Actigraphy is used for pre- and post-diagnostic tracking, especially in insomnia management.

 

3. Home Care Settings

• A fast-emerging segment, home care leverages wearable actigraphy and simplified PSG kits for remote diagnostics.

• Devices are mailed to patients, with data uploaded to cloud dashboards accessed by certified sleep physicians.

• This model supports:

• Patients in rural or underserved areas

• Individuals avoiding hospital visits post-COVID

• Cost-conscious healthcare providers

“The home-based PSG model is saving up to 60% in operational costs for providers, without compromising diagnostic quality,” confirms a U.S.-based telehealth program director.

 

4. Academic & Research Institutions

• Universities and CROs use actigraphy sensors extensively in longitudinal research, circadian rhythm studies , and clinical drug trials .

• These institutions require high-resolution raw data, long battery life, and validated algorithms.

• PSG is deployed for sleep phenotyping and validating new treatment protocols.

 

Featured Use Case Scenario:

A tertiary hospital in South Korea launched a hybrid sleep diagnostics model in 2024. Patients initially wore actigraphy bands at home for seven days, capturing baseline sleep-wake cycles. High-risk patients were then invited for in-lab PSG testing. The dual-pathway model reduced unnecessary lab utilization by 27%, improved diagnostic throughput by 38%, and enabled faster intervention for patients with severe sleep apnea . Additionally, actigraphy data was integrated into their EMR system, allowing for long-term patient monitoring and CBT-I follow-up.

End-user customization is becoming critical. One-size-fits-all no longer works—what matters is flexibility, interoperability, and digital extensibility.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 Years)

• Philips introduced AI-powered enhancements to its SleepMapper platform, allowing seamless integration of PSG and actigraphy data into clinical dashboards. Source:

• SOMNOmedics launched a new generation of wearable PSG systems with 24-hour recording capacity and smartphone-enabled calibration. Source:

• Fitbit Health Solutions , in partnership with academic centers , initiated clinical trials using Fitbit devices as proxy actigraphy tools in long-term insomnia and depression studies. Source:

• The FDA granted clearance to multiple AI-based PSG scoring platforms, accelerating the deployment of fully automated sleep diagnostic workflows. Source:

• Compumedics secured multiple institutional partnerships in Asia Pacific for deploying PSG/EEG systems in public hospitals across China and India. Source:

 

Opportunities

• AI and Data Monetization Models : Integration of actigraphy and PSG data into electronic health records (EHRs), digital therapeutics, and population health platforms is opening new monetization avenues for OEMs.

• Remote Diagnostics Expansion : Growing acceptance of home-based sleep testing is enabling greater access in rural and underserved areas, especially when paired with telemedicine reimbursement.

• Pharma-Research Collaborations : Actigraphy sensors are increasingly being used in clinical trials to capture sleep outcomes as digital biomarkers—creating demand for validated, research-grade wearables.

 

Restraints

• Regulatory Complexity : Varying guidelines across countries for device validation, data protection, and reimbursement limit the scalability of actigraphy and PSG systems—especially for cross-border telehealth services.

• High Capital Costs : PSG systems remain cost-intensive , requiring both hardware and trained technicians. This slows adoption in small clinics or low-resource regions despite increasing awareness.

The actigraphy and PSG market stands at a pivotal moment—where innovation is abundant, but scalability depends on solving reimbursement, training, and integration challenges.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 2.9 Billion
Revenue Forecast in 2030	USD 5.1 Billion
Overall Growth Rate	CAGR of 8.7% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Actigraphy Sensors, Polysomnography Devices
By Application	Sleep Apnea, Insomnia & Circadian Disorders, Narcolepsy, Others
By End User	Sleep Labs, Hospitals & Clinics, Home Care, Research Institutions
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., UK, Germany, China, India, Japan, Brazil, etc.
Market Drivers	Digital sleep health, wearable diagnostics, AI-powered scoring
Customization Option	Available upon request